Algal Bio Acquire EBIS Algae Research Institute To Integrate EPA-rich Nannochloropsis Business

TOKYO, Japan, (March 19, 2025) - Algal Bio, a company specializing in the development of which develops innovativenew products and solutions derived from microalgae, has acquired the   management rights of EBIS Algae Research Institute. This   acquisition is in line with Algal Bio’s mission to with a   commitment to “Cultivating  Algae's Potential for a Better Future”, underscoring its commitment to driving   advancements in the field has acquired the management rights of EBIS Algae   Research Institute. 

AlgalBio acquires management rights to EBIS Algae Industry Research Institute

EBIS Algae Research Institute is a Japan-based company with a rare raceway-based commercialproduction facility for the development, production and marketing of Nannochloropsis (*), amicroalgae containing the highly unsaturated fatty acid EPA (eicosapentaenoic acid), which isessential for sustainable aquaculture and health.

Through this acquisition of management rights, we will develop an integrated microalgae businessfrom R&D to commercial production of a wide variety of microalgae by combining our microalgaebio-foundry platform with EBIS's business infrastructure. In addition to Nannochloropsis for marinefeed, which EBIS already produces and sells, we will accelerate the development of new microalgaespecies for marine feed. Our goal is to become the leading global microalgae company for marinefeed.

About Nannochloropsis: https://www.ebisalgae.com/en/

EBIS’s Microalgae Raceway ponds located in Ishinomaki, Miyagi, Japan

And Nannochloropsis

Since its establishment in 2018, Algal Bio has built a unique microalgae bio-foundry platform with anextensive microalgae library of over 1260 strains of 100 species. Leveraging this platform, we havedeveloped a market-in business model that encompasses the selection and breeding of microalgaespecies for specific applications, the development of cultivation and production technologies, andthe search for optimal production culture conditions. In September 2023, we opened the YokohamaManufacturing Technology Center, which houses a photobioreactor with a maximum capacity of 5tons. We have established a consistent system for researching and developing scale-up culturetechnology.

This business integration will combine EBIS's seawater-based raceway commercial productionfacilities with our microalgae bio-foundry platform to establish a strong technological foundationfrom basic research to commercialization of microalgae. In addition, it will establish a R&D platformthat can meet diverse business needs.

In FY2024, both companies have over 40 joint development projects in operation with clientcompanies that are focused on developing new microalgae products and solutions. The integrationwill also help accelerate the commercialization of each project.

In addition, EBIS is well-known for its high domestic market share in producing and marketing EPArich microalgae feed for fry and juvenile fish. By leveraging the advanced breeding, cultivation, andapplication development technologies developed at our cutting-edge microalgae bio-foundryplatform to EBIS, we aim to become the global market leader in the algae business for marine feed.This will be achieved by developing new products at EBIS using new algae species selected from ourmicroalgae library.

Further updates to the microalgae bio-foundry platform

Realization of consistent promotion of basic research to commercial production

About EBIS Algae Research Institute

Established in 2018. Has a raceway-style commercial production facility in Ishinomaki City, MiyagiPrefecture. EBIS is a specialist in the manufacturing of Nannochloropsis, a marine microalgae that isknown for its high EPA content, and its marine feed products account for over 25% of the domesticmarket.

About Algal Bio

Algal Bio is a R&D-oriented startup company, dedicating to unleashing the potential of microalgaewith the mission of “Cultivating Algae's Potential for a Better Future”. We are building the mostadvanced microalgae bio-foundry platform in the world. Our platform is based on the results ofmore than 20 years of microalgae research at the University of Tokyo. It consists of a proprietarymicroalgae library that accumulates culture data on 1,260 strains of 100 species, as well as breedingand selection technologies for each microalgae, know-how for optimizing culture conditions, and apilot plant for scale-up studies. Our platform will provide the clients with the best possiblemicroalgae for their needs in the shortest possible time. By leveraging our algae bio-foundryplatform, we collaborate with a diverse range of companies to bring new algae-derived productsand solutions to market. These innovations address critical global challenges, including humanhealth, sustainable food supply, and climate change.

For more info: https://algalbio.co.jp/en/

<Contact>

Algal Bio Co., Ltd.

Tel：+81- 4-7138-6207

E-mail：info@algalbio.co.jp

URL：https://algalbio.co.jp/en/